TOPIC

/ company

CSPC Pharmaceutical

CSPC Pharmaceutical researches, develops, manufactures and sells pharmaceutical products. It produces active pharmaceutical ingredients as well as formulations. The company's manufacturing facilities are primarily located in Hebei province.

Chairman / President

Cai Dongchen

CEO / Managing Director

Cai Dongchen

CFO / Finance Director

Wang Huaiyu

Industry

Health & Pharmaceuticals

Website

e-cspc.com

Headquarters address

CSPC Tower, 8 Zhongguancun Avenue, Haidian District, Beijing, China

Stock Code

SEHK:1093

Year founded

1986

A pharmaceutical manufacturing line. Photo: Shutterstock

China’s private sector

Can AI collaborations power China’s next wave of blockbuster drug deals?

China develops 30 per cent of new therapies worldwide as it rises to the top tier in innovation efficiency, drug supervision official says.

13 Jul 2026 - 8:40PM

China’s private sector

China AI drug-design deals swell as US scrutiny mounts

2 Jul 2026 - 7:00PMvideocam

China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

7 Jun 2026 - 7:00PM

China’s private sector

How China’s ‘landmark’ drug pricing guidelines could be a boon for biotech

State Council calls for ‘value-based pricing’ for innovative drugs, a move researchers said would benefit private healthcare players.

22 Apr 2026 - 4:15PM

Chinese biotech firms reached 157 agreements to out-licence early-stage drugs last year. Photo: Shutterstock

Biomedicine: Companies

China biotech deals hit record as innovative drugs draw global interest

Deals reach US$60 billion in first quarter after analysts say Chinese biotech firms have shown substantial technological advancements.

29 Mar 2026 - 7:26PM

Hong Kong stock market

Hong Kong stocks slip, led by tech firms, after Beijing’s OpenClaw warning

Tencent and Alibaba lose ground while CATL and Geely buck market trend.

11 Mar 2026 - 5:17PM

Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

5 Mar 2026 - 11:01AM

Hong Kong stock market

Hong Kong stocks extend rebound from tech turbulence as sentiment returns

Traders move on to focus on coming US economic data that could reshape the path to monetary easing by the Federal Reserve.

10 Feb 2026 - 4:59PM

Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

13 Jan 2026 - 7:30AM

Hong Kong stock market

Hong Kong stocks rise on tech, health as mainland China turnover hits record

Alibaba Health soars over paediatric drug deal as trading volume on Shanghai and Shenzhen exchanges tops US$513 billion.

12 Jan 2026 - 5:08PM

The Exchange Square in Central. Photo: Jelly Tse

Hong Kong stock market

Hong Kong stocks cap longest win streak in 3 weeks as US inflation cools

Soft US inflation data strengthens the case for monetary easing as the Hang Seng Index gains for a third day.

19 Dec 2025 - 4:58PM

General view of the Exchange Square in Central. Photo: Jelly Tse

Hong Kong stock market

Hong Kong stock rally extends as investors bet on US-China trade agreement

Investors shrug off US President Donald Trump’s mention of a 155 per cent tariff on Chinese goods if negotiations fail.

21 Oct 2025 - 4:35PM

Biomedicine: Industry Trends

China’s drug developers stretch to become a global force

Although a start-up’s recent triumph is seen as a ‘DeepSeek moment’, domestic players still trail world-beating pharma firms, experts say.

4 Oct 2025 - 10:56AM

Hong Kong stock market

Hong Kong stocks slip from 4-year high amid fears of US sanctions on drug makers

The Trump administration has been discussing severe restrictions on medicines from China, according to The New York Times.

11 Sep 2025 - 4:43PM

Hong Kong stocks fell on Thursday. Photo: EPA

New medical drugs

Chinese biotech’s mega drug-licensing deals with multinationals surge

Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.

30 May 2025 - 1:30PM

Good mid-stage drug candidates from China at prices far below those in the US market are driving an increase in licensing deals, analysts say. Photo: Shutterstock

Hong Kong stock market

Hong Kong stocks complete sixth week of gains on upbeat China outlook

Jiangsu Hengrui’s strong Hong Kong debut boosts Chinese pharmaceutical stocks.

23 May 2025 - 4:40PM

Hong Kong stock market

China’s first rate cut in 7 months drives Hong Kong stocks to 2-month high

Lower borrowing costs will be a major driver for stocks, Guotai Haitong Securities analysts Fang Yi says.

20 May 2025 - 4:35PM

Hong Kong stock market

Hong Kong stocks rise as investors await earnings from Chinese banks

HSBC gains 3 per cent to HK$88.35 after first-quarter profit beat estimates, announces US$3 billion share buy-back plan.

29 Apr 2025 - 4:36PMvideocam

An electronic billboard shows the various indices of the Hong Kong stock exchange. Photo: AFP

Biomedicine: Companies

Chinese biotech firms cash in on promising drug discoveries via licensing

China has 4,804 new drug candidates under development, second only to the US at 5,268, according to data provider PharmCube.

7 Feb 2025 - 5:45PMvideocam

Health & Fitness

China expands health insurance coverage with 91 new drugs, innovative treatments

The health authority shows its support for novel drugs, while driving tough bargains with pharmaceutical firms on prices.

29 Nov 2024 - 4:42PMvideocam

Chinese coronavirus vaccines

China approves trials of home-grown mRNA vaccines as cases surge

The approvals add CanSino and CSPC to the race among Chinese companies to use mRNA to fight the coronavirus, offering viable alternatives to the vaccines already in production by Pfizer and Moderna.

4 Apr 2022 - 6:19PMvideocam

A billboard promoting vaccinations outside a shopping mall in Beijing. Photo: AFP

CSPC shares plunge after director John Zhao Huan sells 11.95pc stake

CSPC Pharmaceutical Group saw its share price fall 6.7 per cent to HK$6.28 yesterday after the company announced the discounted sale of an 11.95 per cent stake in the firm to a third party to cash out HK$4.4 billion.

28 May 2014 - 1:00AM

John Zhao, an executive director of CSPC Pharmaceutical, sold an 11.95 per cent stake in the company. Photo: SCMP

Help preserve 120 years of quality journalism.

SUPPORT NOW